Selecta Biosciences appoints Carrie Cox to its Board of Directors as Chairman

– USA, MA –  Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR, today announced the appointment of Carrie S. Cox to the position of Chairman of the Board of Directors, effective immediately.

“Ms. Cox has a demonstrated track record of success working with both biotechnology and large pharmaceutical companies. Her addition to our Board of Directors is extraordinarily valuable, as we advance the ImmTOR platform for our lead program, SEL-212, and bring it into the clinic for gene therapy in 2020,” said Carsten Brunn, Ph.D., President and CEO of Selecta Biosciences.

“We are also extremely grateful for the exceptional contributions made by our Co-Founder and outgoing Chairman, Dr. Omid Farokhzad. He established the infrastructure and operational foundation of Selecta, and it is a direct result of his tireless dedication that we are now poised to move to the next stage of our business strategy and advance the ImmTOR platform,” he added.

“I am thrilled with the progress of the ImmTOR platform and I look forward to continuing to work with the Selecta team as a scientific advisor,” said outgoing Chairman, Dr. Farokhzad. “Ms. Cox is an experienced biopharmaceutical executive uniquely suited to lead our Board into the next phase of Selecta’s growth, and we are excited to welcome her to the team.”

About Carrie Cox

Ms. Cox currently serves on the Boards of Directors of Texas Instruments, Cardinal Health, and holds the position of Chair of electroCore. She has also served on the Board of Celgene and held the positions of Lead Director for Texas Instruments, Chairman of Array Biopharma, and Chairman of Prism Pharmaceuticals. She has been named to FORTUNE Magazine’s list of the “50 Most Powerful Women in Business” six times, and her work has been featured in the Harvard Business Review, and in the New York Times bestseller, The Profit Zone. Most recently, Ms. Cox served as Executive Chair of Humacyte, Inc., where she also held the title of CEO from 2010-2018. From 2003 until 2009, she held the positions of Executive Vice President and President, Global Pharmaceuticals, at Schering-Plough. During her tenure, she oversaw the company’s global prescription pharmaceutical business, which generated approximately $16 billion in annual sales, with a 5-year CAGR of 22%. Previous roles include President, Global Prescription Business at Pharmacia Corporation, and Senior Vice President of Global Business Management at Pharmacia & Upjohn.

“The opportunity to be part of a pioneering effort to enhance the application of ImmTOR is of high interest to me,” added Ms. Cox. “As SEL-212 advances into a late-stage asset, and we see the potentially groundbreaking application of ImmTOR in gene therapy, I’m extremely excited to begin this journey and work in collaboration with my Board colleagues to continue the research into the potential application of ImmTOR for patients.”

About Selecta Biosciences, Inc.

Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance technology platform. Selecta plans to combine ImmTOR with a range of biologic therapies for rare and serious diseases that require new treatment options due to high immunogenicity. The company’s current proprietary pipeline includes ImmTOR-powered therapeutic enzyme and gene therapy product candidates. SEL-212, the company’s lead product candidate, is being developed to treat chronic refractory gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta’s proprietary gene therapy product candidates are in preclinical development for certain rare inborn errors of metabolism and incorporate ImmTOR with the goal of addressing barriers to repeat administration. Selecta is based in Watertown, Massachusetts.

For more information: https://selectabio.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>